14 sep: Ambu-aktien sætter rekord: Short-investorer trækker sig ud
15 sep: Bavarian Nordics forsøg med prostatakræft-medicin stoppes
14-09-2017 22:02:13

Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer

Relateret indhold
13 jun - 
Aktier/middag: WDH og GN trækker indekset frem inden re..
12 jun - 
C25-selskaber/Jyske: Dropper dækning af flere selskaber
06 jun - 
Onsdagens aktier: Analysenyt løftede William op i toppe..
Relateret debat
14:44 - 
Ebolavaccine skulle blive et kæmpe hit. Det er ko..
14:29 - 
Nu skriver du 245, den er da kun i 192?  og ser ud..
14:10 - 
hvad er så årsagen til det store fald???

  • Conference call scheduled for 2:00 PM CEST / 8:00 AM EDT tomorrow, Friday, September 15

COPENHAGEN, Denmark, September 14, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that an independent Data Monitoring Committee (DMCB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 PROSPECT study of PROSTVAC® in patients with metastatic castration-resistant prostate cancer (mCRPC) is futile.

"We are extremely disappointed for patients that this study of PROSTVAC as monotherapy was not successful," said Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic. "On behalf of Bavarian Nordic, I want to express our gratitude to the PROSPECT investigators, patients and families who participated in this trial. While this is certainly not the desired outcome, we remain steadfast believers in the power of combination treatments, including immunotherapies, to transform the future of cancer therapies."

The contents of this announcement do not affect the Company's expectations for the financial results for 2017.

Conference call and webcast

The management of Bavarian Nordic will host a conference call tomorrow, Friday, September 15 at 2 PM CEST (8 AM EDT) to discuss the outcome of the interim analysis. Dial-in numbers and link to a live and archived webcast of the conference call will become available at http://www.bavarian-nordic.com/investor/events.aspx?event=5307 during the morning.

About the PROSPECT study

PROSPECT was a global, randomized, double-blind, placebo-controlled Phase 3 study conducted under a Special Protocol Assessment (SPA) from the FDA. The objective of the study was to determine whether PROSTVAC alone or in combination with GM-CSF could prolong overall survival in men with asymptomatic or minimally symptomatic mCRPC. The study enrolled 1,297 patients at more than 200 sites in 15 countries.

About PROSTVAC

PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec, or "rilimogene") is a prostate specific antigen (PSA)-targeted immunotherapy candidate designed to enhance or stimulate the body's immune response, specifically T cells that will home to and kill prostate cancer cells, altering the course of the disease and improving overall survival of patients with prostate cancer. PROSTVAC employs two poxviruses (vaccinia and fowlpox) in a prime-boost vaccine regimen. A robust data package has been established that includes 19 ongoing or completed clinical studies, comprising more than 2,000 patients, the majority of which have been actively treated with PROSTVAC, which has been generally well-tolerated.

PROSTVAC is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its strategic partner Janssen are developing an Ebola vaccine regimen, and therapeutic vaccines for HPV, HBV and HIV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 26 / 2017

2017-26-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 816546.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
18 jun
BAVA
Dvs de bør være der indenfor 9 børsdage... Hvis disse data gentager det som er kommet frem indtil nu..
12
18 jun
BAVA
Jeg har læst vanvittigt mange indlæg du har skrevet om Bavarian, og du bringer mange spændende ting ..
6
09:39
BAVA
Præsentation fra igår for dem der er i tvivl om der er sket noget... http://www.bavarian-nordic.com/..
3
13:17
BAVA
Kopper - accepteret i EU og Canada, godkendes i USA i 2019 Stor kontrakt på ebola Rsv - langt henn..
2
18 jun
BAVA
Aaah sådan noget vrøvl - hvis rsv lykkes, så lykkes den uanset hvad jeg skriver - du er vist overtro..
2
18 jun
BAVA
Bava meddelte på forleden på investordag i Århus, at data fra RSV kommer inden for 14 dage   så rigt..
2
18 jun
BAVA
Disse data er lovet så sent som ifm præsentation for Dansk Aktionærforening den 12/6 - kik her...   ..
2
11:22
BAVA
Den burde falde -  siger geniet, hvorhen? i et hul eller hvad, se lidt mere realistist på aktien.  
1
11:08
BAVA
Du bør vist lige kikke på deres præsentation for 5 år siden også i dag også tænke lidt over det...
1
19 jun
BAVA
Et par google søgninger og fandt frem til den source:  MrBoho      https://www.shareville.dk/medlemm..
1

Ambu: Udenlandske investorer sender aktien mod rekord

20-06-2018 11:18:25
Der er rift om Ambu onsdag formiddag, hvor aktien har sat kursen mod rekord efter en gevinst, der bare har vokset sig større og større i løbet af formiddagen.En rundringning til et par handlere og analytikere har umiddelbart ikke kastet en forklaring af sig.- Der er ingen nyheder ude om Ambu, og vi sidder umiddelbart også og undrer os lidt, siger chefhandler i Danske Bank Mads Zink til Ritzau Fina..

Aktier/tendens: Comeback i sigte - salgstal kan løfte Genmab

20-06-2018 08:30:13
En løftet anbefaling og lovende salgstal fra USA kan løfte Genmab fra åbningen onsdag, hvor udsigterne er noget lysere, end da handlerne slukkede for deres skærme tirsdag eftermiddag.De amerikanske aktier faldt godt nok tirsdag, efter at USA og Kina havde udvekslet nye toldafgifter, men markedet rettede sig noget efter dansk børslukketid, og onsdag morgen peger S&P 500-futuren på en positiv åbning..

Vestas-rival barsler med en vindmølle på mindst 12 MW - citat

19-06-2018 16:42:53
Vindmølleproducenten Senvion har sat sit sigte højt for sin kommende offshore-mølle.Hver af møllerne skal have en kapacitet på minimum 12 megawatt (MW), lyder det ifølge mediet Recharge i en række dokumenter fra det EU-udviklingsprogram, Senvion er med i.Tidligere har Senvion kun oplyst, at udviklingsprojektet drejede sig om en mølle på "10 eller mere" MW. Men det langsigtede mål er at nå op på mø..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Comeback i sigte - salgstal kan løfte Genmab
2
Aktier/åbning: Udlandet løfter Ambu i rekord - Genmab går til tops
3
Genmab/JPM: Hæver anbefalingen og skærer i kursmålet
4
Vestas-rival barsler med en vindmølle på mindst 12 MW - citat
5
Vestas: Konsulenthus spår stigende vækst på vindmøllemarkedet

Relaterede aktiekurser

Bavarian Nordic A/S 193,25 -2,6% Fald i aktiekurs
Bavarian Nordic Ord Shs 193,00 -2,7% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. juni 2018 15:03:04
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180619.1 - EUROWEB1 - 2018-06-20 15:03:04 - 2018-06-20 15:03:04 - 1 - Website: OKAY